Atossa Therapeutics, Inc.’s Post

Read Abby Mallon's article in BioPharma Dive https://lnkd.in/gkNwJGx4 to see how #NurseNavigators and #ClinicalNurseEducators can improve #MedicationAdherence and #PatientEngagement in the oncology space – particularly as more oral therapeutics enter the market.

Solid tumors are a massive challenge for CAR-T - until now? "The first documented complete response in a patient with a solid tumour treated with CAR-T therapy" was reported by AffyImmune Therapeutics. This all came out as part of the deluge of ASCO (American Society of Clinical Oncology) abstracts that were unveiled last week. It's a Phase 1 so we're not popping the champagne yet - but it's a step in the right direction! Article and more deets in the comments below ⬇️ —————————— Comprehensive, daily coverage of the biotech and pharma industry, straight to your inbox (and all in one email) - that's TLDR Biotech. 🧬🔔 #biotech #pharma #pharmanews #biotechnews #tldrbiotech

Alligator Bioscience AB announced positive top-line results from the OPTIMIZE-1 Phase II trial in pancreatic cancer, revealing that mitazalimab combined with mFOLFIRINOX achieved a 40.4% overall response rate (ORR), a median duration of response (DoR) of 12.5 months, and a median overall survival (mOS) of 14.3 months. This compares favorably to the 11.1 months mOS seen with first-line chemotherapies FOLFIRINOX and NALIFIROX. With more than half of the patients still in the study at the primary analysis, the 18-month survival follow-up data was presented at American Society of Clinical Oncology (ASCO) 2024. Get Ahead with Expert Insights and Full Analysis through DelveInsight Business Research LLP's Exclusive ASCO 2024 Coverage: https://lnkd.in/gZDPhuxR #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

Thoughts on this? >> UroGen touts long duration of response for its bladder cancer chemotherapy gel >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #biotech #pharmaceutical

Risk factors for oral cancer: Thematic trends and research agenda. https://ow.ly/i7z550Qx2LO #OralCancer #SystematicReview #Pharmacology #Pharmacy

CAR T-Cell Therapy Market Surges Globally in 2024: #NorthAmerica Leads with $1.56B, Followed by Europe, Asia-Pacific, and LAMEA! #2024 marks a paradigm shift in the treatment of #cancer: the global market for CAR T-cell therapy is dominated by North America, with a $1.56 billion market share, followed by #Europe ($554.44 million), #AsiaPacific ($336.09 million), and #LAMEA ($66.67 million). This innovative treatment represents a significant advancement in #cancertreatment, offering numerous patients throughout the globe a possibility of recovery and opening the door to a better, #healthierfuture. Explore the market overview: https://lnkd.in/gs5XNSAp.       Key Market Players: Juno Therapeutics, Inc., Celyad Oncology, Intellia Therapeutics, Inc., Sorrento Therapeutics, Inc.,Caribou Biosciences, Novartis , Gilead Sciences, Autolus Therapeutics, Pfizer, bluebird bio Cellectis, Bristol Myers Squibb, Cartesian Therapeutics    #AMR #CAR_TCellTherapy #GlobalHealthcare #CancerTreatment #MedicalInnovation #AlliedMarketResearch #NorthAmerica #Europe #AsiaPacific #LAMEA #HealthcareTrends #2024Projections

🔬 Revolutionize oncology care with TuMinimize! Our advanced therapeutic drug monitoring tool ensures that each cancer patient receives precisely the right dose of biologics, tailored to their unique treatment needs. By optimizing dosage, TuMinimize enhances outcomes, reduces adverse effects, and supports healthcare professionals in providing truly personalized care. Learn more: https://lnkd.in/eZB_YbXz. #Oncology #PrecisionMedicine

The #oncology #radiopharmaceutical market is advancing rapidly, with several key players vying for market share. IQVIA's experience and expertise reshape trial pipeline to overcome complexities and executive development process in phase I - IV. Read the fact sheet to learn more: https://bit.ly/4eFQJrq #Radiotherapy #Radiooncology

Thoughts on this? >> FDA approves Roche's new treatment for subset of breast cancer patients >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #healthcare #productmarketing #pharmaceutical

Do you want to understand how our TAC-T cell technology co-opts the body’s natural immune functions to target specific #tumors? Or how our #celltherapy is advancing in the clinic? Check out our latest feature in Pharmaceutical Executive, where Jeffrey Erickson, VP of Business Development, explains how our #cuttingedge #cancer treatment works: https://bit.ly/3PMtIIH